Navigation Links
63 percent of RA patients suffer psychiatric disorders, with depressive spectrum conditions most likely
Date:6/12/2009

Copenhagen, Denmark, Friday 12 June 2009: Over half (63%) of patients with rheumatoid arthritis (RA) also suffer from psychiatric disorders, with the majority of these (87%) occurring in the depressive spectrum, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Interestingly, over half (52%) of the patients studied indicated that they had experienced stress events before the onset of their RA.

The study also revealed a number of other interesting findings about the emotional burden of RA:

  • Cognitive dysfunction was diagnosed in 23% of patients, with 16% of this attributed to depression
  • A third (33%) suffered from sleep disorders
  • Those with depression also exhibited more severe RA (measured by X-ray), greater functional insufficiency and pain, as well as having received less aggressive treatment than patients without depression. (No significant differences in age, duration of illness, gender or DAS28* scores were noted between the two groups)
  • Significantly, cognitive impairments were found more often (p=0.02) in patients older than 50 years (39% vs. 9%)
  • The age of the first prednisone intake was significantly higher (p<0.05) in patients with depression compared to those without (48 vs. 30 years)

Dr Tatiana Lisitsyna from the State Institute of Rheumatology RAMS, Russian Federation, who conducted the study, said: "Psychiatric disorders are a very common comorbidity for people with RA, and they tend to be stress-related and associated with disease activity and chronic pain. Evaluating and addressing the mental health of those with RA should be a regular feature of rheumatology practice to improve quality of life and reduce the potentially distressing psychological burden of RA."

In the study, the disease activity of 75 patients with American College of Rheumatology (ACR) defined RA (96% female, median age 52 years (46-55), median disease duration 12 years (4-22) was assessed using DAS28* with a median score of 4.98 (3.71 - 6.4). Median prednisone intake duration was 34 months (3-72) and 80% of patients were taking DMARDs (49% methotrexate; 23% leflunomide). Using the Brief Pain Inventory (BPI) scale to assess pain, 74% were considered to have either severe (7-10 points) or moderate (5-6 points) pain.

Psychiatric disorders were diagnosed in accordance with the ICD-10 (International Classification of Disease) scale, and other psychiatric and psychological scales used included: the Hospital Anxiety and Depression Scale for screening, the Hamilton Anxiety Rating Scale and the Montgomery-Asberg Depression Rating Scale. Projective psychological methods were employed for evaluation of cognitive function.

* DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is. It assesses number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR, a blood marker of inflammation), and the patient's 'global assessment of global health'. A higher score indicates more active disease.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Allscripts Announces Convertibility of its Outstanding 3.50 Percent Senior Debentures
2. Over 60 percent of all US bankruptcies attributable to medical problems
3. Cardinal Health Increases Quarterly Dividend By 25 Percent
4. Niutang to Expand Sucralose Capacity 66 Percent by 2012
5. New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products
6. National study finds youth baseball-related injuries down 25 percent
7. New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent
8. MedPro Imaging Reports 118 Percent Growth For First Quarter
9. Consumer Reports Poll: Thirty-One Percent of Americans Never Use Sunscreen
10. Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
11. GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
Breaking Medicine Technology: